BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Net loss			$ (4,457,401)	$ (1,441,393)
Amortization of right-of-use assets			14,918	67,097
Accumulated deficit	$ (96,101,634)		(96,101,634)			$ (91,644,233)
Stockholders' equity	32,119,574	$ 43,669,058	32,119,574	43,669,058	$ 34,546,682	$ 36,043,028	$ 44,007,783	$ 39,284,295
Revenue	13,206,717	$ 12,363,429	27,791,190	$ 24,713,206
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]
Net cash used in operations			4,622,989
Working capital	8,593,711		8,593,711
Amortization of right-of-use assets			1,606,650
Cash proceed	$ 629,426		$ 629,426
Proceeds from sale of common stock			901,488